Related Experiment Video

Updated: Jun 13, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Treatment approaches for primary CNS lymphomas

Matteo G Carrabba1, Michele Reni, Marco Foppoli

  • 1San Raffaele Scientific Institute, Haematology and Bone Marrow Transplantation Unit, Department of Oncology, Milan, Italy.

Expert Opinion on Pharmacotherapy
|May 1, 2010
PubMed
Abstract

Insights

High-dose methotrexate-cytarabine combination is the current standard for primary central nervous system lymphoma (PCNSL) treatment. Future research requires well-designed trials and biological studies to improve patient outcomes.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Clinical trial design

Background:

  • Primary central nervous system lymphomas (PCNSL) are rare, potentially curable tumors with unsatisfactory outcomes.
  • Challenges in clinical trials and limited biological knowledge hinder progress in PCNSL management.
  • Despite difficulties, modest progress in PCNSL patient outcomes has been observed.

Purpose of the Study:

  • To review conventional and investigational treatments for PCNSL.
  • To identify key questions for future clinical trials in PCNSL.
  • To outline a 5-year management scenario for PCNSL.

Main Methods:

  • Comprehensive literature search of PubMed and author files using terms 'PCNSL', 'primary CNS lymphoma', and 'CNS lymphoma'.
  • Inclusion of all English-language papers published before November 2009.
  • Focus on treatment paradigms, clinical trial data, and future research directions.

Main Results:

  • The treatment paradigm for PCNSL shifted in the 1990s from radiotherapy to high-dose methotrexate-cytarabine combination chemotherapy.
  • Phase II studies show promising data for current and novel therapeutic approaches.
  • A 5-year outlook for PCNSL management is presented, highlighting evolving treatment strategies.

Conclusions:

  • The methotrexate-cytarabine combination is the current reference treatment for PCNSL.
  • Further improvements in PCNSL outcomes necessitate well-designed randomized trials.
  • Biological studies utilizing novel technologies are crucial for advancing PCNSL patient care.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...